Search

Your search keyword '"Lund, Lars H"' showing total 2,463 results
Start Over Author "Lund, Lars H"
2,463 results on '"Lund, Lars H"'

1. A novel model of cardiovascular–kidney–metabolic syndrome combining unilateral nephrectomy and high-salt–sugar–fat diet in mice

Author

Carvalho, Lucas Rannier R. A., Shimari, Miho, Boeder, Ariela Maína, Zhuge, Zhengbing, Cai, Min, Leijding, Cecilia, Gastaldello, Stefano, Kleschyov, Andrei L., Schiffer, Tomas A., Guimarães, Drielle Dantas, Picozzi, Gaia, Lund, Lars H., Fellström, Bengt, Weitzberg, Eddie, Lundberg, Jon O., Hagberg, Carolina E., Pironti, Gianluigi, Andersson, Daniel C., and Carlström, Mattias

Published
2024
Full Text
View/download PDF

4. Epigenetic modulators link mitochondrial redox homeostasis to cardiac function in a sex-dependent manner

Author

ElBeck, Zaher, Hossain, Mohammad Bakhtiar, Siga, Humam, Oskolkov, Nikolay, Karlsson, Fredrik, Lindgren, Julia, Walentinsson, Anna, Koppenhöfer, Dominique, Jarvis, Rebecca, Bürli, Roland, Jamier, Tanguy, Franssen, Elske, Firth, Mike, Degasperi, Andrea, Bendtsen, Claus, Menzies, Robert I., Streckfuss-Bömeke, Katrin, Kohlhaas, Michael, Nickel, Alexander G., Lund, Lars H., Maack, Christoph, Végvári, Ákos, and Betsholtz, Christer

Published
2024
Full Text
View/download PDF

9. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic

Author

Gajewski, Piotr, Błaziak, Mikołaj, Urban, Szymon, Garus, Mateusz, Braunschweig, Frieder, Caldeira, Daniel, Gawor, Antoni, Greenwood, John P., Guzik, Mateusz, Halfwerk, Frank R., Iwanek, Gracjan, Jarocki, Michał, Jura, Maksym, Krzystek-Korpacka, Małgorzata, Lewandowski, Łukasz, Lund, Lars H., Matysiak, Michał, Pinto, Fausto, Sleziak, Jakub, Wietrzyk, Weronika, Sokolski, Mateusz, Biegus, Jan, Ponikowski, Piotr, and Zymliński, Robert

Published
2023
Full Text
View/download PDF

16. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

Author

Savarese, Gianluigi, Gatti, Paolo, Benson, Lina, Adamo, Marianna, Chioncel, Ovidiu, Crespo-Leiro, Maria G., Anker, Stefan D., Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, McDonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo F., Rosano, Giuseppe M.C., Ruschitzka, Frank, Seferovic, Petar, Volterrani, Maurizio, Maggioni, Aldo P., and Lund, Lars H.

Published
2024
Full Text
View/download PDF

22. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation

Author

Gasparovic, Hrvoje, Jakus, Nina, Brugts, Jasper J., Pouleur, Anne-Catherine, Timmermans, Philippe, Rubiś, Pawel, Gaizauskas, Edvinas, Van Craenenbroeck, Emeline M., Barge-Caballero, Eduardo, Grundmann, Sebastian, Paolillo, Stefania, D’Amario, Domenico, Braun, Oscar Ö., Meyns, Bart, Droogne, Walter, Wierzbicki, Karol, Holcman, Katarzyna, Planinc, Ivo, Lovric, Daniel, Flammer, Andreas J., Petricevic, Mate, Biocina, Bojan, Lund, Lars H., Milicic, Davor, Ruschitzka, Frank, and Cikes, Maja

Published
2022
Full Text
View/download PDF

24. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

Author

Pitt, Bertram, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Komajda, Michel, Testani, Jeffrey M., Wilcox, Christopher S., Ponikowski, Piotr, Lopes, Renato D., Ezekowitz, Justin A., Sun, Franklin, Davies, Michael J., Verma, Subodh, Kosiborod, Mikhail N., and Steg, Ph. Gabriel

Published
2023
Full Text
View/download PDF

34. Heart transplantation outcomes for rheumatic heart disease: Analysis of international registry data

Author

Dan, Jennifer M, Enciso, Jorge Silva, Lund, Lars H, and Aslam, Saima

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Rare Diseases, Autoimmune Disease, Heart Disease, Transplantation, Cardiovascular, Organ Transplantation, 2.4 Surveillance and distribution, Good Health and Well Being, Female, Follow-Up Studies, Graft Rejection, Graft Survival, Heart Transplantation, Humans, Incidence, International Agencies, Male, Middle Aged, Postoperative Complications, Prognosis, Prospective Studies, Registries, Rheumatic Heart Disease, Risk Factors, Survival Rate, ISHLT, rheumatic heart disease, transplantation, Surgery, Clinical sciences
Abstract

BackgroundRheumatic heart disease (RHD), an autoimmune sequela of Group A streptococcal infection, is a chronic valvular disease affecting 32 million people worldwide, predominantly in developing nations. As the predisposition to autoimmune sequela still remains post transplantation, our primary objective was to assess if there were differences in mortality and rejection rates.Methods and resultsUsing the International Society for Heart and Lung Transplantation (ISHLT) adult heart transplant registry, we identified 42 RHD patients who had undergone heart transplantation between 1988 and 2014. We matched the 42 RHD recipients by transplant year, age, and gender to 420 dilated cardiomyopathy (DCM) recipients. One-year mortality in the RHD group was 17.95% vs. 7.92% in the DCM group (P = 0.07). Survival was significantly reduced in the RHD group vs. the DCM group via Kaplan Meier curves (P = 0.04). In a multivariate model, RHD status (OR 3.19, 95% CI 1.15-8.83, P = 0.025) and serum creatinine (OR 1.41, 95% CI 1.09-1.82, P = 0.009) were associated with an increased odds of one-year mortality (P = 0.0013).ConclusionsAt one year post transplantation, RHD recipients had a significantly lower survival than DCM recipients. RHD status was also an independent predictor of mortality at 1 year post transplantation.

Published
2018

39. Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.

Author

Stolfo, Davide, Benson, Lina, Lindberg, Felix, Dahlström, Ulf, Käck, Oskar, Sinagra, Gianfranco, Lund, Lars H., and Savarese, Gianluigi

Subjects
ANGIOTENSIN-receptor blockers, LIVING alone, HEART failure patients, VENTRICULAR ejection fraction, HEART failure
Abstract

Aims: We explored timing, settings and predictors of angiotensin receptor–neprilysin inhibitor (ARNI) initiation in a large, nationwide cohort of patients with heart failure (HF) with reduced ejection fraction (HFrEF). Methods and results: Patients with HFrEF (ejection fraction <40%) registered in the Swedish HF Registry in 2017–2021 and naïve to ARNI were evaluated for timing and location of, and their characteristics at ARNI initiation. ARNI use increased from 8.3% in 2017 to 26.7% in 2021. Among 3892 hospitalized patients, 8% initiated ARNI in‐hospital or ≤14 days after discharge, 4% between 15 and 90 days, and 88% >90 days after discharge or never initiated. Factors associated with earlier initiation included follow‐up in specialized HF care, more severe HF, previous HF treatment use and higher income, whereas older age, higher comorbidity burden and living alone were associated with later/no initiation. Of 16 486 HFrEF patients, 8.1% inpatients and 5.9% outpatients initiated an ARNI at the index date. Factors associated with initiation in outpatients were overall consistent with those linked with an in‐hospital/earlier ARNI initiation; 4.9% of 10 209 with HF duration <6 months and 9.1% of 5877 with HF duration ≥6 months initiated ARNI. Predictors of ARNI initiation in HF duration <6 months were inpatient status, lower ejection fraction, hypertension, whereas previous angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker use was associated with less likely initiation. Discontinuation at 1 year ranged between 13% and 20% across the above‐reported analyses. Conclusions: In‐hospital and early initiation of ARNI are limited in real‐world care but still slightly more likely than in outpatients. ARNI were more likely initiated in patients with more severe HF, which might suggest its use as a second‐line treatment and only following worsening of clinical status. One‐year discontinuation rates were consistent regardless of the timing/setting of ARNI initiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design.

Author

Lund, Lars H., James, Stefan, DeVore, Adam D., Anstrom, Kevin J., Fudim, Marat, Aaronson, Keith D., Dahlström, Ulf, Desvigne‐Nickens, Patrice, Fleg, Jerome L., Yang, Song, Fu, Michael, Hage, Camilla, Held, Claes, Karlström, Patric, Nygren, Magnus, Peterson, Eric D., Pol, Tymon, Sapp, Shelly, Sundström, Johan, and Östlund, Ollie

Subjects
*MINERALOCORTICOID receptors, *HEART failure, *HOSPITAL admission & discharge, *VENTRICULAR ejection fraction, *BODY mass index
Abstract

Aims Methods Conclusion Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF) is a unique pragmatic registry‐based randomized controlled trial.SPIRRIT‐HFpEF is a multicentre, prospective, randomized, open‐label, blinded endpoint trial conducted on platforms in the Swedish Heart Failure Registry (SwedeHF) and the United States (US) Trial Innovation Network. Patients with HFpEF/HFmrEF are randomized 1:1 to spironolactone (or eplerenone) in addition to usual care, versus usual care alone. The primary outcome is total number of cardiovascular deaths and hospitalizations for heart failure. Outcomes are collected from Swedish administrative complete coverage registries and a US call centre and subsequently adjudicated. Simple eligibility criteria were based on data available in SwedeHF: heart failure as outpatient or at discharge from hospital, left ventricular ejection fraction ≥40%, N‐terminal pro‐B‐type natriuretic peptide >300 ng/L (in sinus rhythm) or >750 ng/L (in atrial fibrillation), with pre‐specified adjustment for elevated body mass index, and chronic loop diuretic use. Power and sample size assessments were based on an event‐driven design allowing enrolment over approximately 6 years, and application of hazard ratios from the TOPCAT trial, Americas subset. The final sample size is expected to be approximately 2400 patients.SPIRRIT‐HFpEF will be informative on the effectiveness of generic MRAs in HFpEF and HFmrEF, and on the feasibility of conducting pragmatic and registry‐based trials in heart failure and other chronic conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry.

Author

Lund, Lars H., Crespo‐Leiro, Maria Generosa, Laroche, Cécile, Zaliaduonyte, Diana, Saad, Aly M., Fonseca, Candida, Čelutkienė, Jelena, Zdravkovic, Marija, Bielecka‐Dabrowa, Agata M., Agostoni, Piergiuseppe, Xuereb, Robert G., Neronova, Kseniya V., Lelonek, Malgorzata, Cavusoglu, Yuksel, Gellen, Barnabas, Abdelhamid, Magdy, Hammoudi, Naima, Anker, Stefan D., Chioncel, Ovidiu, and Filippatos, Gerasimos

Subjects
*MINERALOCORTICOID receptors, *VENTRICULAR ejection fraction, *HEART failure, *EMERGENCY medical services, *HOSPITAL emergency services
Abstract

Aims Methods and results Conclusion We analysed baseline characteristics and guideline‐directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry.Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62–79], 36% women) or outpatient visit for HF (61%, age 66 [58–75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC‐affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre‐existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin–angiotensin system inhibitor, angiotensin receptor–neprilysin inhibitor, beta‐blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF.Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC‐affiliated countries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC.

Author

Abdin, Amr, Wilkinson, Chris, Aktaa, Suleman, Böhm, Michael, Polovina, Marija, Rosano, Giuseppe, Lainscak, Mitja, Lund, Lars H., McDonagh, Theresa, Metra, Marco, Adamo, Marianna, Mindham, Richard, Piepoli, Massimo, Abdelhamid, Magdy, Störk, Stefan, Tokmakova, Maria P., Seferović, Petar, Coats, Andrew J.S., and Gale, Chris P.

Abstract

Aims: To update the European Society of Cardiology (ESC) quality indicators (QIs) for the evaluation of the care and outcomes of adults with heart failure. Methods and results: The Working Group comprised experts in heart failure including members of the ESC Clinical Practice Guidelines Task Force for heart failure, members of the Heart Failure Association, and a patient representative. We followed the ESC methodology for QI development. The 2023 focused guideline update was reviewed to assess the suitability of the recommendations with strongest association with benefit and harm against the ESC criteria for QIs. All the new proposed QIs were individually graded by each panellist via online questionnaires for both validity and feasibility. The existing heart failure QIs also underwent voting to 'keep', 'remove' or 'modify'. Five domains of care for the management of heart failure were identified: (1) structural QIs, (2) patient assessment, (3) initial treatment, (4) therapy optimization, and (5) patient health‐related quality of life. In total, 14 'main' and 3 'secondary' QIs were selected across the five domains. Conclusion: This document provides an update of the previously published ESC QIs for heart failure to ensure that these measures are aligned with contemporary evidence. The QIs may be used to quantify adherence to clinical practice as recommended in guidelines to improve the care and outcomes of patients with heart failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC

Author

Savarese, Gianluigi, primary, Lindberg, Felix, additional, Cannata, Antonio, additional, Chioncel, Ovidiu, additional, Stolfo, Davide, additional, Musella, Francesca, additional, Tomasoni, Daniela, additional, Abdelhamid, Magdy, additional, Banerjee, Debasish, additional, Bayes‐Genis, Antoni, additional, Berthelot, Emmanuelle, additional, Braunschweig, Frieder, additional, Coats, Andrew J.S., additional, Girerd, Nicolas, additional, Jankowska, Ewa A., additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lopatin, Yury, additional, Lund, Lars H., additional, Maggioni, Aldo P., additional, Moura, Brenda, additional, Rakisheva, Amina, additional, Ray, Robin, additional, Seferovic, Petar M., additional, Skouri, Hadi, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Rosano, Giuseppe M.C., additional

Published
2024
Full Text
View/download PDF

49. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis

Author

D'Amario, Domenico, primary, Laborante, Renzo, additional, Bianchini, Emiliano, additional, Ciliberti, Giuseppe, additional, Paglianiti, Donato Antonio, additional, Galli, Mattia, additional, Restivo, Attilio, additional, Stolfo, Davide, additional, Vergallo, Rocco, additional, Rosano, Giuseppe M.C., additional, Crea, Filippo, additional, Lam, Carolyn S.P., additional, Lund, Lars H., additional, Metra, Marco, additional, Patti, Giuseppe, additional, and Savarese, Gianluigi, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results